Andrea F. Wainer - 17 Aug 2021 Form 4 Insider Report for ABBOTT LABORATORIES (ABT)

Role
EXECUTIVE VICE PRESIDENT
Signature
/s/ Andrea F. Wainer by Jessica H. Paik, Attorney-in-Fact
Issuer symbol
ABT
Transactions as of
17 Aug 2021
Net transactions value
-$1,217,000
Form type
4
Filing time
19 Aug 2021, 18:27:40 UTC
Previous filing
07 Jun 2021
Next filing
03 Sep 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABT Common shares without par value Options Exercise $211,500 +4,500 +9% $47.00 54,282 17 Aug 2021 Direct
transaction ABT Common shares without par value Options Exercise $384,000 +10,000 +18% $38.40 64,282 17 Aug 2021 Direct
transaction ABT Common shares without par value Sale $1,812,500 -14,500 -23% $125.00 49,782 17 Aug 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABT Option (right to buy) Options Exercise $0 -4,500 -9.5% $0.000000 42,726 17 Aug 2021 Common Shares 4,500 $47.00 Direct F1
transaction ABT Option (right to buy) Options Exercise $0 -10,000 -22% $0.000000 35,000 17 Aug 2021 Common Shares 10,000 $38.40 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.

Remarks:

These transactions were made pursuant to a previously adopted plan complying with Rule 10b5-1(c).